EUVIMEDEUVIMED entdecken
Crossref

Lymphopenia and Circulating Biomarker Dynamics Associated with Clinical Outcome and Toxicity in Pazopanib-Treated Radioiodine-Refractory Thyroid Cancer: Exploratory Analyses from the Pazothyr Trial

Céline Rodriguez, Cécile Dalban, Amélie Colombe-Vermorel, Laetitia Odeyer, Livia Lamartina, Yann Godbert, Frederic Illouz, Julien Gautier, Isabelle Treilleux, Sophie Darnis, Christophe Caux, Christelle de la Fouchardière und 1 weitere

Thyroid® · 10.11.2026

DOI: 10.1177/10507256261500974 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thyroid®, online erschienen am 10.11.2026. Verfasst von Céline Rodriguez und 12 weiteren Autor:innen. Beteiligte Einrichtung: Lyon Immunotherapy for Cancer Laboratory (LICL), Cancer Research Center of Lyon, Léon Bérard Cancer Center, Lyon, France. Die Arbeit nennt 62 Literaturangaben. Gefördert von: Direction Générale de l’offre de Soins, Région Rhône Alpes, Cancéropole Lyon Auvergne Rhône-Alpes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pazopanib showed clinical activity in progressive radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC), although its use is limited by substantial toxicity not reduced by intermittent treatment. We aimed to identify biomarkers associated with outcome and treatment-related toxicity in these patients.

Methods

This study reported exploratory results related to the Pazothyr trial (NCT01813136) investigating pazopanib efficacy in RAIR-DTC patients. We evaluated lymphopenia and neutrophil-to-lymphocyte ratio (NLR) from the Pazothyr clinical database ( n = 168). Dedicated informed consent for additional plasma and tumor sample collection allowed quantification of plasma angiogenic factors and cytokines at baseline and after one month of pazopanib ( n = 111). Immune markers (CD8, FOXP3, CD163, and PDL1) analyzed by immunohistochemistry in archived primary tumors from patients ( n = 68) with response or stable disease after 6 months of pazopanib were scored semiquantitatively. Associations with response, progression-free survival (PFS), overall survival (OS), and substantial treatment-related adverse events (TRAEs) were evaluated. Given the exploratory nature of this study, no adjustment for multiple comparisons was performed.

Results

At baseline, moderate and severe lymphopenia were associated with shorter PFS, unlike high NLR. Elevated Vascular Endothelial Growth Factor A (VEGF-A), Interleukin 6 (IL-6), and CXCL8 correlated with poorer PFS. High VEGF-A, hepatocyte growth factor (HGF), IL-6, CXCL8, and CXCL9 were associated with shorter OS. X Early changes in placental growth factor (PlGF), HGF, interleukin 12 subunit p40, and CXCL10 were associated with substantial TRAEs. Multivariable analyses identified baseline severe lymphopenia (hazard ratio [HR] = 2.39 [confidence interval or CI 1.27–4.48], p = 0.007) and high CXCL8 (HR = 2.01 [CI 1.26–3.21], p = 0.004) as independent factors associated with progression. High baseline NLR (HR = 2.26 [CI 1.21–4.22], p = 0.01), HGF (HR = 2.37 [CI 1.33–4.20], p = 0.003), and CXCL8 (HR = 2.20 [CI 1.25–3.87], p = 0.006) were similarly associated with death. One-month increases in PlGF (odds ratio [OR] = 2.49 [CI 1.13–5.50], p = 0.024) and HGF (OR = 2.91 [CI 1.32–6.43], p = 0.008) were independently associated with substantial TRAEs. In patients with tumor samples, Programmed cell Death-Ligand 1 (PDL1)-immune cell score (ICS) >1% (HR = 2.05 [CI 1.15–3.66], p = 0.015) was also associated with progression.

Conclusions

Baseline lymphopenia and inflammatory plasma biomarkers were associated with clinical outcome, whereas early changes in circulating factors were associated with substantial TRAEs. These exploratory results require prospective validation in RAIR-DTC patients treated with pazopanib or other VEGF receptor-targeting multikinase inhibitors. The relevance of PDL1-ICS expression for anti-PD1/PDL1-based therapies requires dedicated prospective trials.

Schlagwörter

Stichwörter der Autor:innen

PDL1cancer biomarkerscytokineslymphopeniapazopanibradioactive iodine–refractory thyroid cancer

Autor:innen und Institutionen

  • Lyon Immunotherapy for Cancer Laboratory (LICL), Cancer Research Center of Lyon, Léon Bérard Cancer Center, Lyon, France.
  • Department of Clinical Research and Innovation, Léon Bérard Cancer Center, Lyon, France.
  • PATHEC, Léon Bérard Cancer Center, Lyon, France.
  • Medical Imaging Department, Endocrine Cancerology Department, Gustave Roussy, Villejuif, France.
  • Nuclear Medicine and Endocrine Oncology Department, Institut Bergonié, Bordeaux, France.
  • Department of Endocrinology, CHU Angers, Angers, France.

ORCID-Profile: Christine Ménétrier-Caux

Förderung

  • Direction Générale de l’offre de Soins
  • Région Rhône Alpes
  • Cancéropole Lyon Auvergne Rhône-Alpes
  • LabEx DEvweCAN

Zitieren

APA

Rodriguez, C., Dalban, C., Colombe-Vermorel, A., Odeyer, L., Lamartina, L., Godbert, Y., Illouz, F., Gautier, J., Treilleux, I., Darnis, S., Caux, C., de la Fouchardière, C., & Ménétrier-Caux, C. (2026). Lymphopenia and Circulating Biomarker Dynamics Associated with Clinical Outcome and Toxicity in Pazopanib-Treated Radioiodine-Refractory Thyroid Cancer: Exploratory Analyses from the Pazothyr Trial. Thyroid®. https://doi.org/10.1177/10507256261500974

Vancouver

Rodriguez C, Dalban C, Colombe-Vermorel A, Odeyer L, Lamartina L, Godbert Y, et al. Lymphopenia and Circulating Biomarker Dynamics Associated with Clinical Outcome and Toxicity in Pazopanib-Treated Radioiodine-Refractory Thyroid Cancer: Exploratory Analyses from the Pazothyr Trial. Thyroid®. 2026. doi:10.1177/10507256261500974

BibTeX
@article{Rodriguez2026,
  author = {Rodriguez, Céline and Dalban, Cécile and Colombe-Vermorel, Amélie and Odeyer, Laetitia and Lamartina, Livia and Godbert, Yann and Illouz, Frederic and Gautier, Julien and Treilleux, Isabelle and Darnis, Sophie and Caux, Christophe and de la Fouchardière, Christelle and Ménétrier-Caux, Christine},
  title = {Lymphopenia and Circulating Biomarker Dynamics Associated with Clinical Outcome and Toxicity in Pazopanib-Treated Radioiodine-Refractory Thyroid Cancer: Exploratory Analyses from the Pazothyr Trial},
  journal = {Thyroid®},
  year = {2026},
  doi = {10.1177/10507256261500974}
}
Kostenlos starten →